Edition:
United Kingdom

Becton Dickinson and Co (BDX.N)

BDX.N on New York Stock Exchange

231.37USD
17 Jan 2018
Change (% chg)

$2.83 (+1.24%)
Prev Close
$228.54
Open
$230.28
Day's High
$231.38
Day's Low
$226.99
Volume
566,948
Avg. Vol
353,354
52-wk High
$231.38
52-wk Low
$169.23

Chart for

About

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of... (more)

Overall

Beta: 1.04
Market Cap(Mil.): $45,076.07
Shares Outstanding(Mil.): 227.57
Dividend: 0.73
Yield (%): 1.47

Financials

  Industry Sector
P/E (TTM): -- 32.18 16.44
EPS (TTM): -- -- --
ROI: -- 13.94 10.61
ROE: -- 16.77 14.21

BRIEF-BD Statement On FDA Warning Letter For Preanalytical Systems Business Unit

* BD STATEMENT ON FDA WARNING LETTER FOR PREANALYTICAL SYSTEMS BUSINESS UNIT

12 Jan 2018

BRIEF-FDA Issues Warning Letter To Becton Dickinson & Co

* FDA WARNS BECTON DICKINSON & COMPANY OF SIGNIFICANT VIOLATIONS OF THE LAW AS PART OF ONGOING INVESTIGATION INTO LEAD TESTING ISSUES‍​

11 Jan 2018

UPDATE 1-Becton Dickinson's $24 bln takeover of C R Bard set to close after China nod

* Becton had said China approval was last hurdle for deal to close

28 Dec 2017

China commerce ministry conditionally approves Becton Dickinson-C R Bard merger

BEIJING China's commerce ministry said on Thursday that it has conditionally approved a merger between U.S. medical equipment supplier Becton Dickinson and its U.S. peer C R Bard .

28 Dec 2017

China commerce ministry conditionally approves Becton Dickinson-C R Bard merger

BEIJING, Dec 28 China's commerce ministry said on Thursday that it has conditionally approved a merger between U.S. medical equipment supplier Becton Dickinson and its U.S. peer C R Bard.

28 Dec 2017

Becton, Dickinson to divest two product lines for C R Bard buy: FTC

WASHINGTON U.S. medical equipment supplier Becton Dickinson and C R Bard have agreed to divest two product lines to satisfy U.S. Federal Trade Commission concerns their proposed $24 billion merger would negatively affect competition.

22 Dec 2017

UPDATE 1-Becton, Dickinson to divest two product lines for C R Bard buy -FTC

WASHINGTON, Dec 22 U.S. medical equipment supplier Becton Dickinson and C R Bard have agreed to divest two product lines to satisfy U.S. Federal Trade Commission concerns their proposed $24 billion merger would negatively affect competition.

22 Dec 2017

BRIEF-BD Issues Statement On FTC Clearance Of Bard Acquisition

* EXPECT BARD DEAL WILL CLOSE IN DECEMBER, PENDING APPROVAL BY CHINA MINISTRY OF COMMERCE, SOME OTHER CONDITIONS Source text for Eikon: Further company coverage:

22 Dec 2017

Becton, Dickinson agrees to divest two product lines for C R Bard buy -FTC

WASHINGTON, Dec 22 U.S. medical equipment supplier Becton Dickinson and C R Bard have agreed to divest two product lines to settle U.S. Federal Trade Commission charges that Becton, Dickinson's proposed $24 billion acquisition of Bard would negatively impact competition in those markets, the FTC said on Friday.

22 Dec 2017

BRIEF-Becton Dickinson And Co Says CEO Vincent Forlenza's FY 2017 Total Compensation Was $13.1 Mln

* BECTON DICKINSON AND CO SAYS CHAIRMAN AND CEO VINCENT FORLENZA'S FY 2017 TOTAL COMPENSATION WAS $13.1 MILLION VERSUS $13.9 MILLION IN FY 2016 - SEC FILING Source text: (http://bit.ly/2ktIxQL) Further company coverage:

14 Dec 2017

Earnings vs. Estimates